Profile
Sector:
HealthcareIndustry:
BiotechnologyCountry:
United StatesIPO:
16 December 1993Website:
http://arrowheadpharma.comNext earnings report:
07 August 2024Last dividends:
N/ANext dividends:
N/APrice
after hours | Fri, 05 Jul 2024 23:52:59 GMTDividend
Analysts recommendations
Institutional Ownership
ARWR Latest News
PASADENA, Calif.--(BUSINESS WIRE)---- $arwr--Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced plans to advance investigational plozasiran into a Phase 3 cardiovascular outcomes trial called CAPITAN. This comes after promising results were recently announced from multiple clinical trials in three distinct patient populations, including the pivotal Phase 3 PALISADE study in patients with genetically confirmed or clinically diagnosed familial chylomicronemia syndrome (FCS), the Phase 2 SHASTA-.
PASADENA, Calif.--(BUSINESS WIRE)---- $arwr--Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced that preclinical data on ARO-INHBE, an investigational RNAi-based medicine for the treatment of obesity and metabolic diseases, were presented at the American Diabetes Association (ADA) 84th Scientific Sessions, which were held June 21-24, in Orlando, FL, and virtually. The preclinical results demonstrate that ARO-INHBE substantially silenced hepatic expression of the INHBE gene, which has been ide.
PASADENA, Calif.--(BUSINESS WIRE)---- $arwr--Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced topline results from the pivotal Phase 3 PALISADE study of investigational plozasiran in patients with genetically confirmed or clinically diagnosed familial chylomicronemia syndrome (FCS), a severe genetic disease with significant unmet need and no FDA approved therapies. PALISADE successfully met the primary endpoint of lowering triglycerides and met all key secondary endpoints, including reducin.
PASADENA, Calif.--(BUSINESS WIRE)---- $arwr--Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced that it is scheduled to participate in the following upcoming events: 16th European Glaucoma Society (EGS) Congress – June 1-4, 2024 Title: Development and Characterization of Trabecular Meshwork Targeted RNAi Molecule Platform via Intracameral Administration for Glaucoma Date/Time: June 2, 2024, 10:30 a.m. IST Session: Poster Section Jefferies Global Healthcare Conference – June 5-6, 2024 Type: Fi.
PASADENA, Calif.--(BUSINESS WIRE)---- $arwr--Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced results from the Phase 2b double blind, randomized ARCHES-2 study of investigational zodasiran (formerly ARO-ANG3) in patients with mixed hyperlipidemia. Zodasiran was associated with robust and durable reductions in triglycerides, triglyceride rich lipoprotein remnants, and total atherogenic lipoproteins, including LDL-C. These data were presented in a late-breaking oral presentation today at the.
PASADENA, Calif.--(BUSINESS WIRE)---- $arwr--Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced results from the Phase 2b double blind, randomized MUIR study of investigational plozasiran (formerly ARO-APOC3) in patients with mixed hyperlipidemia. Treatment with plozasiran in the MUIR study achieved reductions in triglyceride rich lipoproteins, a genetically validated target associated with increased risk of atherosclerotic cardiovascular disease (ASCVD)1,2. These data were presented in an or.
PASADENA, Calif.--(BUSINESS WIRE)---- $arwr--Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced that new interim clinical data on ARO-RAGE, an investigational RNAi-based medicine for the treatment of inflammatory lung diseases, such as asthma, were presented at the American Thoracic Society (ATS) 2024 International Conference. Interim results from the ongoing Phase 1/2 study demonstrate that treatment with ARO-RAGE led to a reduction in soluble RAGE (sRAGE) concentration in bronchoalveolar la.
If you're unsure about which stocks to purchase this month, you've come to the right place. All investors hope for their chosen stocks to increase significantly in value.
While the technology sector has been enjoying ridiculous returns, it's inevitable that a slowdown (or even a correction) may materialize, which brings to the table biotech stocks. This is just as innovative of sector as “regular” tech but it just hasn't received the same fervor.
After closing out 2023 with a 15.1% gain, the Russell 2000 looks even better this year in the new year. In fact, since Jan. 2, the index is up about 4% year to date, and could push even higher, taking some of the most undervalued Russell 2000 stocks along for the ride.
- 1(current)
What type of business is Arrowhead Pharmaceuticals?
Arrowhead Pharmaceuticals, Inc. is a biopharmaceutical company focused on developing innovative drugs for the treatment of genetically based diseases. Current clinical developments are focused on treating liver diseases, lung diseases, and malignant tumors. The company was founded in 1989 and is headquartered in Pasadena, California. Despite its considerable experience in the industry, Arrowhead Pharmaceuticals Inc. is still in the early stages of drug development. The research facilities of Arrowhead are located in Madison, Wisconsin. The company does not own any real estate, as its office and research center are leased.
What sector is Arrowhead Pharmaceuticals in?
Arrowhead Pharmaceuticals is in the Healthcare sector
What industry is Arrowhead Pharmaceuticals in?
Arrowhead Pharmaceuticals is in the Biotechnology industry
What country is Arrowhead Pharmaceuticals from?
Arrowhead Pharmaceuticals is headquartered in United States
When did Arrowhead Pharmaceuticals go public?
Arrowhead Pharmaceuticals initial public offering (IPO) was on 16 December 1993
What is Arrowhead Pharmaceuticals website?
https://arrowheadpharma.com
Is Arrowhead Pharmaceuticals in the S&P 500?
No, Arrowhead Pharmaceuticals is not included in the S&P 500 index
Is Arrowhead Pharmaceuticals in the NASDAQ 100?
No, Arrowhead Pharmaceuticals is not included in the NASDAQ 100 index
Is Arrowhead Pharmaceuticals in the Dow Jones?
No, Arrowhead Pharmaceuticals is not included in the Dow Jones index
When does Arrowhead Pharmaceuticals report earnings?
The next expected earnings date for Arrowhead Pharmaceuticals is 07 August 2024